Adjuvant Selpercatinib Improves Survival in RET Fusion-Positive NSCLC
Clinical Summary:
- Design/Population: The phase 3 LIBRETTO-432 trial assessed adjuvant selpercatinib in patients with RET fusion-positive non-small cell lung cancer who underwent definitive locoregional therapy.
- Key Outcomes: Selpercatinib significantly improved event-free survival compared with placebo with a safety profile that consistent with prior experience.
- Clinical Relevance: Adjuvant selpercatinib may provide a new targeted treatment option for patients with early-stage RET fusion-positive non-small cell lung cancer.
Jonathan Goldman, MD, University of California, Los Angeles, California, discusses results from the phase 3 LIBRETTO-432 trial which evaluated adjuvant selpercatinib in patients with early-stage RET fusion-positive non-small cell lung cancer (NSCLC) who previously underwent definitive local therapy.
Results demonstrated that selpercatinib significantly improved event-free survival (EFS) compared with placebo with a safety profile that was consistent with prior findings.
Dr Goldman presented these results during a plenary session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Source:
Goldman JW, Yang X, Hochmair M, et al. Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial. Presented at the ASCO Annual Meeting. May 29 - June 2, 2026. Chicago, Illinois. LBA3.
